Expression of Serum PSA, Nesfatin-1, and AMH in Patients with Polycystic Ovary Syndrome

Yan Wang1, Xiaorong Ma2, Jiashou Luo1, Xiaoyan Wang3, Lu Han2*

1Department of Obstetrics and Gynecology, The Affiliated Nanping First Hospital of Fujian Medical University, Nanping 353000, China
2Department of Gynecology, The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
3Department of Obstetrics and Gynecology, Jianou Maternal and Child Health Care Center, Jianou 353100, China

ARTICLE INFO

Original paper
Article history:
Received: August 09, 2021
Accepted: November 12, 2021
Published: December 15, 2021

Keywords:
PCOS; PSA; Nesfatin-1; AMH; Feeding Inhibitory Factor

ABSTRACT

Insulin resistance and hyperandrogenism are the leading causes of polycystic ovary syndrome (PCOS). Therefore, it has great significance to study the expression levels of PSA, nesfatin-1, and AMH. To provide some reference for clinical diagnosis and treatment of polycystic ovary syndrome (PCOS), the expression levels of PSA, nesfatin-1, and AMH in serum of patients with polycystic ovary syndrome (PCOS) were investigated. The experimental group consisted of 200 patients with polycystic ovary syndrome treated in Shanghai Huashan Hospital from July 2018 to July 2019. The control group consisted of 150 healthy women without pregnancy. The PSA, nesfatin-1, and AMH levels in serum were detected by chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA). The serum levels of prostate-specific antigen (PSA) and anti-Mullerian hormone (AMH) were 16.53 ± 0.67pg/ml and 10.75 ± 4.02pg/ml in the experimental group (PCOS patients), which were significantly higher than those in the control group (3.27 ± 0.43pg/ml and 5.18 ± 1.84pg/ml, respectively), while the inhibitive factors in the experimental group (1.89 ± 0.99mg/ml) were significantly higher than those in the control group (1.10 ± 0.97mg/ml). There was no significant difference in nesfatin-1. The levels of PSA and nesfatin-1, nesfatin-1, and AMH in patients with polycystic ovary syndrome (PCOS) were positively correlated, and the differences were statistically significant. The levels of PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome of different ages were different, and the differences were significant and negatively correlated with the age increasing. PSA, nesfatin-1, and AMH levels in patients with polycystic ovary syndrome were significantly different from those in control nonpregnant women. There was a certain correlation between the levels of PSA, nesfatin-1, and AMH, and age. The results have specific clinical reference significance for the diagnosis and treatment of patients with polycystic ovary syndrome.

Copyright: © 2021 by the C.M.B. Association. All rights reserved.

Introduction

Polycystic ovary syndrome is a disease caused by endocrine disorders in women of childbearing age (1). With the accelerated pace of life, the incidence rate of diseases has increased year by year, which has seriously disturbed people's lives (2). The main clinical manifestations are hyperandrogenemia, irregular uterine bleeding and ovarian cysts (young patients are affected by the menstrual disorder of hairy infertility, while the middle-aged and elderly patients are affected by cardiovascular diseases and diabetes mellitus), which can lead to infertility in 72 percent of patients, accompanied by insulin resistance and obesity (3, 4). It has seriously affected the lives of women of all ages. If not treated for a long time, it will seriously affect reproductive health and even general health. With the development of social medicine, people pay more and more attention to PCOS, and the clinical diagnosis and treatment methods are also constantly updated (5).

The pathogenesis of PCOS is complex. It is regulated by multiple hormones and may be affected by the environment and genes. Because of its unclear etiology, the treatment has not been cured. At present, some abnormal indexes of PCOS patients are mainly monitored and symptomatically treated in the clinic (6, 7). At present, the indexes for detecting PCOS patients are mainly three sex hormones, such as...
foll...
collection, blood volume 4-6ml (without anticoagulant), and timely detection.

2. Sample processing: after the specimens were placed at room temperature for 0.5h, centrifugation (4000rpm, 5min), serum was separated and detected in time. The samples that failed to be detected in time were stored in the refrigerator at -80°C for use, and they need to be dissolved completely.

3. Determination of AMH: electrochemiluminescence immunoassay

   The detection method of AMH is mainly using the electrochemiluminescence immune system, which has high sensitivity, and the detection range is 0.01-23ng/ml. The specific operation steps refer to the manual of the conventional kit.

4. For the determination of nesfatin-1, an enzyme-linked immunosorbent assay (ELISA) was used. Refer to the manual of the conventional kit for specific operation steps.

5. PSA determination: radioimmunoassay was used. All samples were taken and Roche E170 and e1010 electrochemiluminescence instruments were used for determination. The specific operation steps were referred to the manual of conventional kit, which was provided by Roche pharmaceutical company.

Data processing

SPSS statistical software and Excel were used for data analysis. The results of the evaluation process were expressed in the form of mean ± standard error (x ± SEM). An independent sample t-test was used to compare the numerical data between groups. P < 0.05 means the difference is significant, and P < 0.01 means the difference is extremely significant.

Results and discussion

Comparison of serum FSH, LH and T in PCOS patients and healthy controls

The serum luteinizing hormone (LH) level of the experimental group (PCOS patients) was 18.01 ± 0.26mu/l, and that of the normal group was 8.02 ± 2.65u/l, the difference was statistically significant (P < 0.001); the testosterone (T) level of PCOS group was 5.23 ± 0.56mu/l, which was significantly higher than that of the normal group (6.12 ± 1.05mu/l), but the difference was not statistically significant. The level of follicle-stimulating hormone (FSH) in PCOS group was 2.96 ± 0.68 mmol / L, which was significantly lower than that in the normal group (0.95 ± 0.20 mmol / L), but the difference was statistically significant (P < 0.05) (Figure 1).

Comparison of serum FINS, FPG and HOMA - IR between PCOS patients and healthy controls

The serum fasting insulin (fins) level in the experimental group (PCOS patients) was 15.28±5.26mu/l, and that of the normal group was 7.32±2.14u/l, the difference was statistically significant (P < 0.001); the fasting blood glucose (FPG) level of the PCOS group was 5.19±0.56mmol/l, which was significantly higher than that of the normal group (4.42± 1.35mmol/l). The level of HOMA-IR in PCOS group was 4.56±1.38, which was significantly higher than that in the normal group (1.35±0.72), but the difference was statistically significant (P < 0.001) (Table 1 and Figure 2).

Table1. Comparison of FINS, FPG and HOMA-IR between the experimental group and the control group (x±s)

| Group | FINS(mU/L) | FPG(mmol/L) | HOMA-IR       |
|-------|------------|-------------|---------------|
| CG    | 7.32±2.14  | 4.42±1.35   | 1.35±0.72     |
| EG    | 15.28±5.26**| 5.19±0.56   | 4.56±1.38**   |
|       |            |             | HOMA-IR=FINS(mU/L)XFPG(mmol/L)/22.5 |

Figure 1. Comparison of FSH, LH and T in experimental group and control group (x ± s)

Figure 2. Comparison of FINS, FPG and HOMA-IR between the experimental group and the control group (x±s)
Comparison of serum PSA, Nesfatin-1 and AMH levels between PCOS patients and healthy controls

The serum prostate-specific antigen (PSA) level in the experimental group (PCOS patients) was 16.53±0.67pg/ml, and that of the normal group was 3.27±0.43pg/ml, the difference was statistically significant (P < 0.001); the level of nestatin-1 in PCOS group was 1.89±0.99ng/ml, which was significantly higher than that in the normal group (factor 1 (nesfatin-1 level was 1.10 ± 0.97mg/ml, but the difference was not statistically significant (P > 0.05)); the level of anti-Mullerian hormone (AMH) in PCOS group was 10.75± 4.02pg/ml, which was significantly higher than that of normal group (5.18±1.84pg/ml), but the difference was statistically significant (P < 0.001), as Table 2.

Table 2. Comparison of serum PSA, Nesfatin-1 and AMH levels between PCOS patients and healthy controls (x±s); group (G)

| Age  | PSA(pg/mL)   | Nesfatin-1(pg/mL) | AMH(pg/mL) |
|------|--------------|-------------------|-------------|
| CG   | 3.27±0.43    | 1.10±0.97         | 5.18±1.84   |
| EG   | 16.53±0.67** | 1.89±0.99         | 10.75±4.02**|

Comparison of serum PSA, Nesfatin-1 and AMH levels in PCOS patients of different ages

Prostate-specific antigen (PSA): with the increase of age in patients with PCOS, the average value of prostate-specific antigen (PSA) increases continuously, and the growth rate of prostate-specific antigen (PSA) is about 30%. If 95% value is used as the upper limit of reference value for each age group, the reference upper limit of 20-25-year-old group is 14.98 ± 0.28pg/ml, that of 25-30-year-old group is 16.56pg/ml, and that of 30-40-year-old group is 16.56pg/ml The upper limit was 17.08pg/ml; the reference upper limit of 41-45 years old group was 18.47pg/ml; the upper limit of 45-50 years old group was 20.98 ± 0.35pg/ml.

Nesfatin-1: as the age of PCOS patients increases, the average value of nesfatin-1 increases, and the growth rate of nesfatin-1 is about 2.4%. If 95% value is taken as the upper limit of reference value for each age group, the reference upper limit of 20-25-year-old group is 1.76 ± 1.67; ng/ml, the reference upper limit of 25-30-year-old group is 1.90ng/ml; that of 31-40-year-old group is 1.90ng/ml The reference upper limit was 2.06ng/ml; the reference upper limit of 41-45 years old group was 2.18ng/ml; the upper limit of 45-50 years old group was 2.23 ± 1.85ng/ml.

Anti-Mullerian hormone (AMH): with the age of PCOS patients, the average value of anti-Mullerian hormone (AMH) continues to increase, and the growth rate of anti-Mullerian hormone (AMH) is about 29.3%. If 95% value is used as the upper limit of reference value for each age group, the reference upper limit of 20-25-year-old group is 11.88 ± 3.84ng/ml, that of 25-30-year-old group is 10.65ng/ml, and that of 31-40-year-old group is 10.65ng/ml The reference upper limit of 41-45 years old group was 6.75 ng/ml; the upper limit of 45-50 years old group was 6.03 ± 2.65 ng/ml, as Table 3.

Table 3. Comparison of serum levels of PSA, Nesfatin-1 and AMH levels in PCOS patients of different ages

| Age  | PSA(pg/mL) | Nesfatin-1(pg/mL) | AMH(ng/mL) |
|------|------------|-------------------|------------|
| 20-25| 14.98±0.28 | 1.76±1.67         | 11.88±3.84 |
| 25-30| 16.56±0.42 | 1.90±1.97         | 10.65±4.02 |
| 31-40| 17.08±0.81 | 2.06±3.54         | 8.26±3.65  |
| 41-45| 18.47±0.43 | 2.18±2.65         | 6.75±3.16  |
| 45-50| 20.98±0.35 | 2.23±1.85         | 6.03±2.65  |

ROC curve analysis of serum PSA, Nesfatin-1, AMH and sex hormone in the diagnosis of PCOS

The ROC curve analysis of prostate-specific antigen (PSA) and sex hormone in the diagnosis of PCOS showed that the area under the curve (AUC) of prostate-specific antigen (PSA) in the diagnosis of PCOS was the largest (0.820), the sensitivity was 92.3%, and the best cut-off point was 16.56pg/ml.

ROC curve analysis showed that the area under the curve (AUC) of nesfatin-1 in the diagnosis of PCOS was 0.761, the sensitivity was 85.3%, the specificity was 42.2%, and the best cut-off point was 2.24ng/ml.

The ROC curve analysis of anti-Mullerian hormone (AMH) and sex hormone in the diagnosis of PCOS showed that the area under the curve (AUC) of anti-Mullerian hormone (AMH) in the diagnosis of PCOS was the largest (0.854), the sensitivity was 67.3%, the specificity was 92.3%, and the best cut-off point was 6.65ng/ml.

The ROC curve analysis of follicle-stimulating hormone (FSH) and sex hormone in the diagnosis of PCOS showed that the area under the curve (AUC) of FSH in the diagnosis of PCOS was the largest (0.682),
the sensitivity was 92.4%, the specificity was 57.5%, and the best diagnostic cut-off point was 8.27 IU/L.

ROC curve analysis showed that the area under the curve (AUC) of luteinizing hormone (LH) in the diagnosis of PCOS was the largest (0.765), the sensitivity was 76.3%, the specificity was 69.3%, and the best diagnostic cut-off point was 13.44 IU/L.

ROC curve analysis showed that the area under the curve (AUC) of testosterone (T) in the diagnosis of PCOS was the largest (0.769), the sensitivity was 71.8%, the specificity was 73.4%, and the best cut-off point was 0.7 IU/L. (Table 4, Table 5, and Table 6).

Table 4. Efficacy comparison of PSA and sex hormone in the diagnosis of PCOS; index (A), AUC (B), Sensitivity (C), Specificity (D), The best cut-off point of diagnosis (E)

|       | A      | B      | C          | D      | E         |
|-------|--------|--------|------------|--------|-----------|
| PSA   | 0.820  | 95.3   | 83.5       | 16.56pg/mL |
| FSH   | 0.682  | 92.4   | 57.5       | 8.27IU/L |
| LH    | 0.765  | 76.3   | 69.3       | 13.44IU/L |
| T     | 0.769  | 71.8   | 73.4       | 0.7IU/L  |

Table 5. Efficacy comparison of Nesfatin-1 and sex hormone in the diagnosis of PCOS; index (A), AUC (B), Sensitivity (C), Specificity (D), The best cut-off point of diagnosis (E)

|       | A      | B      | C          | D      | E         |
|-------|--------|--------|------------|--------|-----------|
| Nesfatin-1 | 0.761  | 85.3   | 42.2       | 2.24ng/mL |
| FSH    | 0.682  | 92.4   | 57.5       | 8.27IU/L |
| LH     | 0.765  | 76.3   | 69.3       | 13.44IU/L |
| T      | 0.769  | 71.8   | 73.4       | 0.7IU/L  |

Table 6. Efficacy comparison of AMH and sex hormone in the diagnosis of PCOS; index (A), AUC (B), Sensitivity (C), Specificity (D), The best cut-off point of diagnosis (E)

|       | A      | B      | C          | D      | E         |
|-------|--------|--------|------------|--------|-----------|
| AMH   | 0.854  | 67.3   | 92.3       | 6.65ng/mL |
| FSH   | 0.682  | 92.4   | 57.5       | 8.27IU/L |
| LH    | 0.765  | 76.3   | 69.3       | 13.44IU/L |
| T     | 0.769  | 71.8   | 73.4       | 0.7IU/L  |

Diagnostic value of serum PSA, Nesfatin-1 and AMH in PCOS

The AUC of PSA diagnosis of PCOS was 0.821, 95% CI was 0.653-0.854; the AUC of nesfatin-1 diagnosis of PCOS was 0.763, 95% CI was 0.682-0.836; AUC of AMH diagnosis of PCOS was 0.753, 95% CI was 0.706-0.802; AUC of PSA + nesfatin-1 + AMH diagnosis of PCOS was 0.915, 95% CI was 0.915. The area under the curve of PSA + nesfatin-1 + AMH was significantly higher than that of PSA + nesfatin-1 + AMH (z = 4.649, 8.155, 2.917, 7.583 3 3, P < 0.05); the specificity and accuracy of combined detection of PSA, nesfatin-1 and AMH were 90.65%, 91.79% and 93.24%, respectively (Figures 3 and 4).

Polycystic ovary syndrome (PCOS) is an endocrine disorder, which occurs in women of gestational age. Some studies believe that the occurrence of polycystic ovary syndrome is related to genetic and environmental factors (17). At the same time, a large number of studies focus on the influence of chronic inflammation and autoimmune on polycystic ovary syndrome. As an important factor in ovarian regulation, cytokines play an important role in regulating the process from primordial follicle to primary folliculogenesis (18). This study focused on the expression of PSA, nesfatin-1 and AMH in patients with polycystic ovary syndrome and their correlation.
PSA is an important indicator of prostate cancer in men (19). In recent years, it has been found that PSA is expressed in women's ovary and endometrium, and it is further found that PSA is closely regulated by similar steroids. Some studies suggest that androgen binding to the PSA receptor can promote the expression of PSA and further regulate the level of PSA. From the results of this study, the PSA level of patients with polycystic ovary syndrome is significantly higher than that of normal people, which is consistent with the results reported in the previous literature (20, 21). At the same time, because the level of PSA in women is very low, it shows that PSA can be used as a monitoring index in the diagnosis of polycystic ovary syndrome.

AMH is a kind of transforming growth factor, its main role is to regulate early follicular recruitment. It was not detected in atresia follicles and hormone-dependent dominant follicles. Studies have found that AMH is positively correlated with the number of antral follicles and primordial follicles, and the level of AMH in patients with polycystic ovary syndrome is higher than that in healthy people. According to the results of this study, the level of AMH in patients with polycystic ovary syndrome is significantly higher than that of normal people, which is consistent with the results reported in the previous literature (22). The possible reason for this significant difference is that AMH inhibits the development of primordial follicles. At the same time, the detection of AMH is of great significance in the early screening of PCOS.

Nesfatin-1 is a neuropeptide. Some studies have shown that nesfatin-1 is involved in the occurrence and development of sex hormones and insulin resistance. That is, nesfatin-1 can affect the production and secretion of sex hormones through the hypothalamus-pituitary gonad (23). The relationship between LH, FSH and serum nesfatin-1 in patients with polycystic ovary syndrome was studied. The results showed that the level of nesfatin-1 in patients with polycystic ovary syndrome was significantly lower than that in healthy people, and there was a negative correlation between serum nesfatin-1 and sex hormones, which was consistent with the previous literature (23). This syndrome is very effective in individual, family and social life and needs to be seriously researched (24).

In conclusion, PSA, nesfatin-1 and AMH play an important role in the formation and development of the pathological mechanism of PCOS patients. Detection of serum PSA, nesfatin-1 and AMH levels in PCOS patients will help to understand the pathological causes of PCOS and guide the diagnosis and treatment of PCOS more accurately.

Acknowledgments
None.

Interest conflict
The authors declare no conflict of interest.

References
1. Ganie MA, Zargar MA, Parvez T, Rashid F. The ICAM-1 Gly241Arg Polymorphism is Not Associated With Polycystic Ovary Syndrome-Results from a Case Control study in Kashmir, India. Asian Pac J Cancer Prev 2016; 17(3): 1583-1588.
2. Gollu AN, Gore CA. Knowledge, awareness and attitude of medical students regarding HPV infection and HPV vaccination. Asian Pac j cance care 2021; 6(1): 41-46.
3. Azeez SH, Jafar SN, Aziziaram Z, Fang L, Mawlood AH, Erçisli MF. Insulin-producing cells from bone marrow stem cells versus injectable insulin for the treatment of rats with type I diabetes. Cell Mol Biomed Rep 2021; 1(1): 42-51.
4. Özkcan S, Yılmaz ÖÇ, Yavuz B. Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS). Clin Exp Hypertens 2020; 42(8): 681-684.
5. Sekar N, Nair M, Francis G et al. Multi-parameter approach for evaluation of genomic instability in the polycystic ovary syndrome. Asian Pac J Cancer Prev 2015; 16(16): 7129-7138.
6. Sulaiman NS, Rovina K, Joseph VM. Classification, extraction and current analytical approaches for detection of pesticides in various food products. J Consum Protect Food Safety 2019; 14(3): 209-221.
7. Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: neuroendocrine origins. Trends Endocrinol Metab 2018; 29(12): 841-852.
8. Razali NH, Ali A, Gan SH, Lim CS. Prevalence of Traditional and Complementary Alternative Medicine’s Use among Cancer Patients in South Peninsular Malaysia. Asian Pac j cancer biol 2020; 5(1): 19-26.
9. Tokmak A, Kokanali MK, Guzel AI, Kara A, Topcu HO, Cavkaytar S. Polycystic ovary syndrome and risk of endometrial cancer: a mini-review. Asian Pac J Cancer Prev 2014; 15(17): 7011-7014.
10. Maksymowicz M, Machowiec P, Baran N, Piekarska M. The role of soy in development of breast, ovarian, endometrial and prostate gland cancer. J Educ Health Sport 2021; 11(9): 180-186.
11. Mirzakhani K, Kallenbach J, Rasa SMM et al. The androgen receptor—IncRNAsAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. Oncogene 2021: 1-14.
12. Shwetha Nagaraj D, Naik AL. Prostate Specific Antigen in Women with PCOS and Its Correlation with Total Testosterone. Int J Biotechnol Biochem 2019; 15(2): 87-95.
13. Maleki-Hajigha A, Razavi M, Rezaeinejad M et al. Serum prostate-specific antigen level in women with polycystic ovary syndrome: a systematic review and meta-analysis. Horm Metab Res 2019; 51(04): 230-242.
14. Palasz A, Janas-Kozik M, Borrow A, Arias-Carrion O, Worthington JJ. The potential role of the novel hypothalamic neuropeptides nesfatin-1, phoenixin, spexin and kisspeptin in the pathogenesis of anxiety and anorexia nervosa. Neurochem Int 2018; 113: 120-136.
15. Shi Y, Li L, Zhou J et al. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats. Biomed Pharmacother 2019; 113: 108687.
16. Zeng X, Xie Y-j, Liu Y-t, Long S-l, Mo Z-c. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta 2020; 502: 214-221.
17. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37(5): 467-520.
18. Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet 2019; 12: 249.
19. Ercisli MF, Kahrizi D, Aziziaram Z. Environmental factors affecting the risk of breast cancer and the modulating role of vitamin D on this malignancy. Cent Asian J Environ Sci Technol Innov 2021; 2(4).
20. Ercisli MF, Lechun G, Azeez SH, Hamasalih RM, Song S, Aziziaram Z. Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients. Cell Mol Biomed Rep 2021; 1(1): 33-41.
21. Taghavi SA, Bazarganipour F, Allan H et al. Pelvic floor dysfunction and polycystic ovary syndrome. Hum Fertil 2017; 20(4): 262-267.
22. Jeppesen J, Anderson R, Kelsey T et al. Which follicles make the most anti-Müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Basic Sci Reproduct Med 2013; 19(8): 519-527.
23. García-Galiano D, Navarro VM, Roa J et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci 2010; 30(23): 7783-7792.
24. Kazemi E, Zargooshi J, Fatahi Dehpahni M, Kaboudi M, Mahaki B, Mohammadian Y. Unconsummated Marriage (“Honeymoon Impotence”): 25 years’ Experience with 871 Couples, in Kermanshah, Iran. Tob Regul Sci 2021; 5-2: 5018-5031.